About Editas Medicine
Editas Medicine is a clinical-stage genome editing company that develops genomic medicines for serious diseases.
Headquarters
Editas Medicine, Cambridge
Founded
2013-01-01
Industry
Biotechnology, Genetics, Health Care, Medical
Last Funding Type
Post Ipo Equity
Valuation
0.6
Total Funding
$931.60 million dollars
IPO Status
Public
Financial
Editas Medicine reported a quarterly loss of $0.76 per share, missing the Zacks Consensus Estimate of a loss of $0.63. Revenue for Q1 2024 was $1.14 million, down 89% from the previous year. The company also announced positive data from the phase I/II/III RUBY study of its lead candidate, reni-cel, in 18 patients with sickle cell disease. Additionally, a high-ranking executive sold over 22,000 shares of the company.
Funding Rounds
7
Number of Lead Investors
5
Total Funding Amount
$931.60 million dollars
Number of Investors
19